Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Jonathan Meyer

Title(s)Clinical Professor (Voluntary), Psychiatry
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Switching Patients with Schizophrenia from Intramuscular Paliperidone Palmitate Once Monthly to TV-46000, a Long-Acting Subcutaneous Antipsychotic: Population Pharmacokinetic-Based Strategies. Adv Ther. 2025 Nov; 42(11):5564-5577. Perlstein I, Meyer J, Yue Z, Ivaturi V, Franzenburg KR, Suett M, Hansen R, Merenlender Wagner A, Phatak A, Singh R. PMID: 40920288; PMCID: PMC12579685.
      View in: PubMed   Mentions:
    2. Feasibility and structure of a state hospital botulinum neurotoxin clinic for clozapine-induced sialorrhea. Ann Gen Psychiatry. 2025 Aug 26; 24(1):51. Arias AW, Cummings MA, Proctor GJ, Meyer JM. PMID: 40859322; PMCID: PMC12382142.
      View in: PubMed   Mentions:
    3. ENaC inhibitors for the management of lithium related polyuria: a systematic review. J Affect Disord. 2025 Nov 01; 388:119542. Strawbridge R, Ott M, Werneke U, Abbott MG, Prabhu A, Young AH, Meyer JM. PMID: 40449743.
      View in: PubMed   Mentions:
    4. The efficacy of lithium in the treatment of suicidal ideation, behavior and suicide: An updated systematic review and meta-analysis of randomized controlled trials. J Affect Disord. 2025 Oct 15; 387:119487. Wang JX, Le GH, Wong S, Teopiz KM, Kwan ATH, Rosenblat JD, Rhee TG, Ho R, Lo HKY, Goldberg JF, Vinberg M, Grande I, Mansur R, Meyer JM, McIntyre RS. PMID: 40441661.
      View in: PubMed   Mentions:
    5. Real-world clinical outcomes in adult patients with Fabry disease: A 20-year retrospective observational cohort study from a single centre. Mol Genet Metab Rep. 2025 Jun; 43:101229. McCarron EP, Chinnadurai R, Meyer J, Anderson T, Stepien KM, Sharma R, Woolfson P, Jovanovic A. PMID: 40485669; PMCID: PMC12144493.
      View in: PubMed   Mentions:
    6. Clozapine Monitoring in the Post-REMS World: Some Guidance for Clinicians. J Clin Psychiatry. 2025 May 05; 86(2). Meyer JM, Rubio JM. PMID: 40338261.
      View in: PubMed   Mentions:
    7. From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials. Int J Neuropsychopharmacol. 2025 04 11; 28(4). Meyer JM, Kramer K, Vuocolo S, Kaul I, Miller AC. PMID: 40056428; PMCID: PMC11997306.
      View in: PubMed   Mentions:
    8. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes. J Clin Psychopharmacol. 2025 May-Jun 01; 45(3):197-218. de Leon J, Baldessarini RJ, Balon R, Bilbily J, Caroff SN, Citrome L, Correll CU, Cotes RO, Davis JM, DeLisi LE, Faden J, Freudenreich O, Goldsmith DR, Gurrera R, Josiassen RC, Kane JM, Kelly DL, Keshavan MS, Laitman RS, Lam YWF, Leung JG, Love RC, McCollum B, McGrane IR, Meyer JM, Nasrallah HA, Nucifora FC, Rothschild AJ, Rubio JM, Sajatovic M, Sarpal DK, Schoretsanitis G, Shad M, Shelton C, Sher L, Singh B, Surya S, Zarzar TR, Sanz EJ, De Las Cuevas C. PMID: 40198784; PMCID: PMC12105975.
      View in: PubMed   Mentions:
    9. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I: A Review of the Pharmacokinetic Literature and Proposed Changes. J Clin Psychopharmacol. 2025 May-Jun 01; 45(3):179-196. de Leon J, Baldessarini RJ, Balon R, Bilbily J, Caroff SN, Citrome L, Correll CU, Cotes RO, Davis JM, DeLisi LE, Faden J, Freudenreich O, Goldsmith DR, Gurrera R, Josiassen RC, Kane JM, Kelly DL, Keshavan MS, Laitman RS, Lam YWF, Leung JG, Love RC, McCollum B, McGrane IR, Meyer J, Nasrallah HA, Nucifora FC, Rothschild AJ, Rubio JM, Sajatovic M, Sarpal DK, Schoretsanitis G, Shad M, Shelton C, Sher L, Singh B, Surya S, Zarzar TR, Sanz EJ, De Las Cuevas C. PMID: 40198781; PMCID: PMC12105979.
      View in: PubMed   Mentions:
    10. Tardive dyskinesia versus tardive syndrome. What is in a name? Parkinsonism Relat Disord. 2025 Apr; 133:107295. Frei K, Scott A, Caroff SN, Jankovic J, Ondo W, Citrome L, Hauser R, Friedman JH, Bhidayasiri R, Sajatovic M, Alters D, Meyer J, Factor S, Tan EK, Remington G, Glick I, Fernandez H, Comella C, Kane J, McEvoy J, Miller D, Zai CC, Lindenmayer JP, Trosch R, Truong DD. PMID: 39904646.
      View in: PubMed   Mentions:    Fields:    
    11. How antipsychotics work in schizophrenia: a primer on mechanisms. CNS Spectr. 2024 Dec 02; 30(1):e6. Meyer JM. PMID: 39618418.
      View in: PubMed   Mentions:
    12. Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone. Nature. 2024 Sep; 633(8030):654-661. Dunn ME, Kithcart A, Kim JH, Ho AJ, Franklin MC, Romero Hernandez A, de Hoon J, Botermans W, Meyer J, Jin X, Zhang D, Torello J, Jasewicz D, Kamat V, Garnova E, Liu N, Rosconi M, Pan H, Karnik S, Burczynski ME, Zheng W, Rafique A, Nielsen JB, De T, Verweij N, Pandit A, Locke A, Chalasani N, Melander O, Schwantes-An TH, Penn Medicine Biobank, Baras A, Lotta LA, Musser BJ, Mastaitis J, Devalaraja-Narashimha KB, Rankin AJ, Huang T, Herman G, Olson W, Murphy AJ, Yancopoulos GD, Olenchock BA, Morton L. PMID: 39261724; PMCID: PMC11410649.
      View in: PubMed   Mentions:
    13. Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial. Lancet Infect Dis. 2025 Jan; 25(1):52-67. Isa F, Gonzalez Ortiz AM, Meyer J, Hamilton JD, Olenchock BA, Brackin T, Ganguly S, Forleo-Neto E, Faria L, Heirman I, Marovich M, Hutter J, Polakowski L, Irvin SC, Thakur M, Hooper AT, Baum A, Petro CD, Fakih FA, McElrath MJ, De Rosa SC, Cohen KW, Williams LD, Hellman CA, Odeh AJ, Patel AH, Tomaras GD, Geba GP, Kyratsous CA, Musser B, Yancopoulos GD, Herman GA, Trial Working Group. PMID: 39236733.
      View in: PubMed   Mentions:
    14. An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders. CNS Drugs. 2024 04; 38(4):239-254. Vanegas-Arroyave N, Caroff SN, Citrome L, Crasta J, McIntyre RS, Meyer JM, Patel A, Smith JM, Farahmand K, Manahan R, Lundt L, Cicero SA. PMID: 38502289; PMCID: PMC10980662.
      View in: PubMed   Mentions:
    15. Making sense of norclozapine levels: 3 clinical axioms. Schizophr Res. 2024 06; 268:289-292. Meyer JM. PMID: 37945386.
      View in: PubMed   Mentions:
    16. Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review. Ment Health Clin. 2023 Oct; 13(5):225-232. Meyer JM, Chepke C, Bera RB, Pérez-Rodríguez MM, Lundt L, Franey EG, Dhanda R, Benning B, Bron M, Yonan C. PMID: 38131059; PMCID: PMC10732123.
      View in: PubMed   Mentions: 1  
    17. Reviewing Non-Dopaminergic Mechanisms for Positive and Negative Schizophrenia Symptom Management. J Clin Psychiatry. 2023 08 07; 84(4). Citrome L, Meyer JM. PMID: 37555680.
      View in: PubMed   Mentions:
    18. Comment on "Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison" [Letter]. Neuropsychiatr Dis Treat. 2023; 19:1709-1710. Rege B, Meyer JM. PMID: 37546516; PMCID: PMC10402714.
      View in: PubMed   Mentions:
    19. Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia. CNS Drugs. 2023 07; 37(7):545-570. Meyer JM, Correll CU. PMID: 37470979; PMCID: PMC10374807.
      View in: PubMed   Mentions:
    20. Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations. Expert Opin Drug Metab Toxicol. 2023 Apr; 19(4):189-202. Schoretsanitis G, Meyer JM, Conca A, Hiemke C. PMID: 37259573.
      View in: PubMed   Mentions:
    21. Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients. CNS Spectr. 2023 08; 28(4):478-481. Meyer JM, Simmons A, Jiang Y, Graham C, Yagoda S, McDonnell D. PMID: 36226902.
      View in: PubMed   Mentions:
    22. The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression. CNS Spectr. 2023 08; 28(4):427-440. Van den Eynde V, Abdelmoemin WR, Abraham MM, Amsterdam JD, Anderson IM, Andrade C, Baker GB, Beekman ATF, Berk M, Birkenhäger TK, Blackwell BB, Blier P, Blom MBJ, Bodkin AJ, Cattaneo CI, Dantz B, Davidson J, Dunlop BW, Estévez RF, Feinberg SS, Finberg JPM, Fochtmann LJ, Gotlib D, Holt A, Insel TR, Larsen JK, Mago R, Menkes DB, Meyer JM, Nutt DJ, Parker G, Rego MD, Richelson E, Ruhé HG, Sáiz-Ruiz J, Stahl SM, Steele T, Thase ME, Ulrich S, van Balkom AJLM, Vieta E, Whyte I, Young AH, Gillman PK. PMID: 35837681.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    23. Clozapine Use and Forensic Outcomes in Psychiatric Inpatients Deemed Incompetent to Stand Trial. J Am Acad Psychiatry Law. 2022 Sep; 50(3):427-433. Singh A, Delgado D, Ventura MI, Schwartz E, Williams J, Meyer JM. PMID: 35798392.
      View in: PubMed   Mentions:
    24. Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19. Int J Infect Dis. 2022 Sep; 122:585-592. Isa F, Forleo-Neto E, Meyer J, Zheng W, Rasmussen S, Armas D, Oshita M, Brinson C, Folkerth S, Faria L, Heirman I, Sarkar N, Musser BJ, Bansal S, O'Brien MP, Turner KC, Ganguly S, Mahmood A, Dupljak A, Hooper AT, Hamilton JD, Kim Y, Kowal B, Soo Y, Geba GP, Lipsich L, Braunstein N, Yancopoulos GD, Weinreich DM, Herman GA, ?for the COVID-19 Multi-dose Trial Team. PMID: 35788416; PMCID: PMC9249725.
      View in: PubMed   Mentions:
    25. Impact of Transcatheter Aortic Valve Implantation Among Patients With Co-existing Mild to Moderate Mitral Regurgitation. Am J Cardiol. 2022 08 15; 177:84-89. Twing AH, Gokhale S, Slostad B, Meyer J, Simon E, Dickens H, Kaluzna SD, Groo V, Kansal M, Shroff A, Groves EM. PMID: 35732551.
      View in: PubMed   Mentions:
    26. Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder. BMC Psychiatry. 2022 02 14; 22(1):114. Doane MJ, Bessonova L, Friedler HS, Mortimer KM, Cheng H, Brecht T, O'Sullivan AK, Cummings H, McDonnell D, Meyer JM. PMID: 35164737; PMCID: PMC8842889.
      View in: PubMed   Mentions:
    27. A survey of personnel and services offered in 32 outpatient US clozapine clinics. BMC Psychiatry. 2021 11 19; 21(1):583. Cotes RO, Rolin D, Meyer JM, Young AS, Cohen AN, Gorrindo T. PMID: 34798855; PMCID: PMC8605520.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Management of Pseudobulbar Affect With Fluoxetine and Dextromethorphan. J Clin Psychopharmacol. 2021 Sep-Oct 01; 41(5):601-603. Bent RE, Hwang T, Meyer JM, Rao S. PMID: 34369905.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr. 2022 04; 27(2):208-217. Hauser RA, Meyer JM, Factor SA, Comella CL, Tanner CM, Xavier RM, Caroff SN, Lundt L. PMID: 33213556; PMCID: PMC9249122.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    30. The Cal-DSH diversion guidelines. CNS Spectr. 2020 10; 25(5):701-713. Cummings MA, Scott C, Arguello JC, Arias AW, Breth AM, Delgado D, Harvey PD, Meyer JM, O'Day J, Pollock M, Proctor G, Rector T, Rose B, Schwartz E, Thordarson H, Warburton K, Stahl SM. PMID: 33111661.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    31. Cognitive Impairment in Patients with Breast Cancer before Surgery: Results from a CANTO Cohort Subgroup. Cancer Epidemiol Biomarkers Prev. 2020 09; 29(9):1759-1766. Lange M, Hardy-Léger I, Licaj I, Pistilli B, Rigal O, Le Fel J, Lévy C, Capel A, Coutant C, Meyer J, Lerebours F, Petrucci J, Vanlemmens L, Brion M, Campone M, Soulié P, Blain M, Vaz-Luis I, Giffard B, Martin AL, Everhard S, André F, Dauchy S, Joly F. PMID: 32611581.
      View in: PubMed   Mentions:
    32. A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia. J Clin Psychiatry. 2020 Jan 28; 81(2). Caroff SN, Citrome L, Meyer J, Sajatovic M, Goldberg JF, Jain R, Lundt L, Lindenmayer JP, McEvoy JP, McIntyre RS, Tohen M, Ketter TA. PMID: 31995677.
      View in: PubMed   Mentions:
    33. Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatr Dis Treat. 2019; 15:2537-2550. Correll CU, Jain R, Meyer JM, Periclou A, Carrothers T, Barabássy Á, Patel M, Earley W. PMID: 31507322; PMCID: PMC6719841.
      View in: PubMed   Mentions:
    34. Monitoring and improving antipsychotic adherence in outpatient forensic diversion programs. CNS Spectr. 2020 04; 25(2):136-144. Meyer JM. PMID: 31120002.
      View in: PubMed   Mentions:
    35. Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia. CNS Spectr. 2020 06; 25(3):323-330. Jain R, Meyer J, Wehr A, Rege B, von Moltke L, Weiden PJ. PMID: 31111801.
      View in: PubMed   Mentions:
    36. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. CNS Spectr. 2018 12; 23(6):402-413. Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM. PMID: 30588905.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    37. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed- CORRIGENDUM. CNS Spectr. 2018 04; 23(2):186. Meyer JM. PMID: 29676242.
      View in: PubMed   Mentions:
    38. Future directions in tardive dyskinesia research. J Neurol Sci. 2018 06 15; 389:76-80. Meyer JM. PMID: 29433809.
      View in: PubMed   Mentions:
    39. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. CNS Spectr. 2017 12; 22(S1):14-28. Meyer JM. PMID: 29350127.
      View in: PubMed   Mentions:
    40. Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records. Ann Gen Psychiatry. 2017; 16:36. Meyer JM, Ng-Mak DS, Chuang CC, Rajagopalan K, Loebel A. PMID: 29075309; PMCID: PMC5646018.
      View in: PubMed   Mentions:
    41. Abdominal-pelvic scanning parameters revisited: a case for Z-axis reduction in patients with clinical suspicion for acute appendicitis. Emerg Radiol. 2017 Dec; 24(6):661-666. Patel DC, Huang YH, Meyer J, Sepahdari A. PMID: 28752376.
      View in: PubMed   Mentions:
    42. Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing. BJPsych Bull. 2017 Jun; 41(3):164-168. Moore BA, Morrissette DA, Meyer JM, Stahl SM. PMID: 28584654; PMCID: PMC5451651.
      View in: PubMed   Mentions: 3  
    43. Augmentation of phenelzine with aripiprazole and quetiapine in a treatment-resistant patient with psychotic unipolar depression: case report and literature review. CNS Spectr. 2017 10; 22(5):391-396. Meyer JM, Cummings MA, Proctor G. PMID: 28004621.
      View in: PubMed   Mentions:
    44. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectr. 2016 12; 21(S1):13-24. Meyer JM. PMID: 28044943.
      View in: PubMed   Mentions:
    45. Psychopharmacology of Persistent Violence and Aggression. Psychiatr Clin North Am. 2016 12; 39(4):541-556. Meyer JM, Cummings MA, Proctor G, Stahl SM. PMID: 27836150.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    46. Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction. Case Rep Psychiatry. 2016; 2016:5606098. Meyer JM, Proctor G, Cummings MA, Dardashti LJ, Stahl SM. PMID: 27872784; PMCID: PMC5107233.
      View in: PubMed   Mentions: 8  
    47. Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia. Int Clin Psychopharmacol. 2015 Nov; 30(6):342-50. Meyer JM, Mao Y, Pikalov A, Cucchiaro J, Loebel A. PMID: 26196189; PMCID: PMC4593468.
      View in: PubMed   Mentions:
    48. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Psychopharmacology (Berl). 2015 Sep; 232(18):3297-308. Polcwiartek C, Sneider B, Graff C, Taylor D, Meyer J, Kanters JK, Nielsen J. PMID: 26231497.
      View in: PubMed   Mentions:
    49. California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectr. 2014 Oct; 19(5):449-465. Stahl SM, Morrissette DA, Cummings M, Azizian A, Bader S, Broderick C, Dardashti L, Delgado D, Meyer J, O'Day J, Proctor G, Rose B, Schur M, Schwartz E, Velasquez S, Warburton K. PMID: 28480838.
      View in: PubMed   Mentions: 5     Fields:    
    50. California State Hospital Violence Assessment and Treatment (Cal-VAT) guideline. CNS Spectr. 2014 Oct; 19(5):449-65. Stahl SM, Morrissette DA, Cummings M, Azizian A, Bader S, Broderick C, Dardashti L, Delgado D, Meyer J, O'Day J, Proctor G, Rose B, Schur M, Schwartz E, Velasquez S, Warburton K. PMID: 27358935.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    51. A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr. 2014 Oct; 19(5):432-8. Meyer JM. PMID: 24865765.
      View in: PubMed   Mentions:
    52. The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk. Psychiatry Res. 2014 Aug 15; 218(1-2):201-8. Ferrara M, Umlauf A, Sanders C, Meyer JM, Allen McCutchan J, Duarte N, Hampton Atkinson J, Grant I, Ellis RJ, CHARTER Group. PMID: 24794030; PMCID: PMC4082695.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    53. Schizophrenia: the role of dopamine and glutamate. J Clin Psychiatry. 2014 Mar; 75(3):274-5. Abi-Dargham A, Meyer JM. PMID: 24717380.
      View in: PubMed   Mentions:
    54. Understanding depot antipsychotics: an illustrated guide to kinetics. CNS Spectr. 2013 Dec; 18 Suppl 1:58-67; quiz 68. Meyer JM. PMID: 24345710.
      View in: PubMed   Mentions:
    55. “Meta-guidelines” for the management of patients with schizophrenia. CNS Spectr. 2013 Jun; 18(3):150-162. Stahl SM, Morrissette DA, Citrome L, Saklad SR, Cummings MA, Meyer JM, O'Day JA, Dardashti LJ, Warburton KD. PMID: 23591126.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    56. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs. 2011 Jun 01; 25(6):473-90. Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM. PMID: 21649448.
      View in: PubMed   Mentions:
    57. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res. 2011 May; 128(1-3):166-70. Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D, Davis S, Stroup TS, Swartz M, Lieberman J, Rosenheck R. PMID: 21334853; PMCID: PMC3789238.
      View in: PubMed   Mentions:
    58. Risk factors for ileus in patients with schizophrenia. Schizophr Bull. 2012 May; 38(3):592-8. Nielsen J, Meyer JM. PMID: 21112965; PMCID: PMC3329981.
      View in: PubMed   Mentions:
    59. Use of clinical markers to identify metabolic syndrome in antipsychotic-treated patients. J Clin Psychiatry. 2010 Oct; 71(10):1273-8. Jin H, Meyer J, Mudaliar S, Henry R, Khandrika S, Glorioso DK, Kraemer H, Jeste D. PMID: 21062616.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    60. Real-world Data on Atypical Antipsychotic Medication Side Effects. Psychiatry (Edgmont). 2010 Jul; 7(7):9-12. Cascade E, Kalali AH, Mehra S, Meyer JM. PMID: 20805913; PMCID: PMC2922368.
      View in: PubMed   Mentions:
    61. Antipsychotics and metabolics in the post-CATIE era. Curr Top Behav Neurosci. 2010; 4:23-42. Meyer JM. PMID: 21312396.
      View in: PubMed   Mentions:
    62. Antipsychotic prescribing practices following withdrawal of concomitant carbamazepine. J Psychiatr Pract. 2009 Nov; 15(6):442-8. Strack DK, Leckband SG, Meyer JM. PMID: 19934718.
      View in: PubMed   Mentions:
    63. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009 Nov; 18(11):1715-26. Meyer JM, Loebel AD, Schweizer E. PMID: 19780705.
      View in: PubMed   Mentions:
    64. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry. 2009 Dec 01; 66(11):1013-22. Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, Hsiao JK, Swartz MS, Stroup TS, Lieberman JA. PMID: 19640511; PMCID: PMC3743723.
      View in: PubMed   Mentions:
    65. Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharmacol. 2009 Oct; 19(10):702-7. Nielsen J, Graff C, Hardahl T, Andersen MP, Kristoffersen J, Struijk JJ, Toft E, Meyer JM. PMID: 19457646.
      View in: PubMed   Mentions:
    66. Increased use of antibiotics in patients treated with clozapine. Eur Neuropsychopharmacol. 2009 Jul; 19(7):483-6. Nielsen J, Foldager L, Meyer JM. PMID: 19356909.
      View in: PubMed   Mentions:
    67. Is there a therapeutic window with some antidepressants for analgesic response? Curr Pain Headache Rep. 2009 Apr; 13(2):93-9. Atkinson JH, Patel SM, Meyer JM, Slater MA, Zisook S, Capparelli E. PMID: 19272274.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    68. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009 Jan; 119(1):4-14. Meyer JM, Stahl SM. PMID: 19133915.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansPHPublic Health
    69. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. J Clin Psychiatry. 2009 Mar; 70(3):318-25. Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R. PMID: 19192469.
      View in: PubMed   Mentions:
    70. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophr Res. 2008 Dec; 106(2-3):300-7. Newcomer JW, Meyer JM, Baker RA, Eudicone JM, Pikalov A, Vester-Blokland E, McQuade RD, Crandall DT, Carson WH, Marcus RN, L'italien G. PMID: 18973991; PMCID: PMC3769700.
      View in: PubMed   Mentions:
    71. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008 Oct; 105(1-3):175-87. Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA. PMID: 18775645; PMCID: PMC2614656.
      View in: PubMed   Mentions:
    72. Sexual dysfunction in patients treated with atypical antipsychotics. J Clin Psychiatry. 2008 Sep; 69(9):e26. Meyer JM. PMID: 19026271.
      View in: PubMed   Mentions:
    73. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res. 2008 Aug; 103(1-3):104-9. Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. PMID: 18534821; PMCID: PMC2583138.
      View in: PubMed   Mentions:
    74. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008 Apr; 101(1-3):273-86. Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA. PMID: 18258416; PMCID: PMC3673564.
      View in: PubMed   Mentions:
    75. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res. 2008 Mar; 100(1-3):70-85. Jin H, Meyer JM, Mudaliar S, Jeste DV. PMID: 18206351; PMCID: PMC2699769.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimals
    76. Drug-drug interactions with antipsychotics. CNS Spectr. 2007 Dec; 12(12 Suppl 21):6-9. Meyer J. PMID: 18389925.
      View in: PubMed   Mentions:
    77. Evidence-based psychiatry: outcomes and decisions. South Med J. 2007 Sep; 100(9):861-2. Meyer JM. PMID: 17902282.
      View in: PubMed   Mentions:
    78. Cardiovascular effects of antipsychotics. Expert Rev Neurother. 2007 Jul; 7(7):829-39. Michelsen JW, Meyer JM. PMID: 17610390.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    79. Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans. J Clin Gastroenterol. 2007 Mar; 41(3):322-8. Dollarhide AW, Loh C, Leckband SG, Endow-Eyer R, Robinson S, Meyer JM. PMID: 17426475.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    80. Antipsychotic safety and efficacy concerns. J Clin Psychiatry. 2007; 68 Suppl 14:20-6. Meyer JM. PMID: 18284274.
      View in: PubMed   Mentions:
    81. Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial. J Clin Psychiatry. 2007; 68 Suppl 1:28-33. Meyer JM. PMID: 17286525.
      View in: PubMed   Mentions:
    82. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006 Sep; 86(1-3):15-22. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA. PMID: 16884895.
      View in: PubMed   Mentions:
    83. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract. 2006 Jan; 12(1):5-10. Meyer J, Loh C, Leckband SG, Boyd JA, Wirshing WC, Pierre JM, Wirshing D. PMID: 16432440.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    84. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry. 2006 Jan-Mar; 18(1):23-31. Loh C, Meyer JM, Leckband SG. PMID: 16517450.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    85. Bone mineral density in male schizophrenia patients: a review. Ann Clin Psychiatry. 2006 Jan-Mar; 18(1):43-8. Meyer JM, Lehman D. PMID: 16517452.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    86. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther. 2005 Dec; 27(12):1930-41. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. PMID: 16507379.
      View in: PubMed   Mentions:
    87. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005 Dec 01; 80(1):45-53. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, Lieberman JA. PMID: 16198088.
      View in: PubMed   Mentions:
    88. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005 Dec 01; 80(1):19-32. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. PMID: 16137860.
      View in: PubMed   Mentions:
    89. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res. 2005 Dec 01; 80(1):9-18. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Keefe RS, Stroup TS, Lieberman JA. PMID: 16125372.
      View in: PubMed   Mentions:
    90. The metabolic syndrome and schizophrenia: a review. Int Rev Psychiatry. 2005 Jun; 17(3):173-80. Meyer J, Koro CE, L'Italien GJ. PMID: 16194788.
      View in: PubMed   Mentions:
    91. Lithium toxicity after switch from fosinopril to lisinopril. Int Clin Psychopharmacol. 2005 Mar; 20(2):115-8. Meyer JM, Dollarhide A, Tuan IL. PMID: 15729089.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    92. Atypical antipsychotic therapy and hyperlipidemia: a review. Essent Psychopharmacol. 2005; 6(3):148-57. Koro CE, Meyer JM. PMID: 15869022.
      View in: PubMed   Mentions:
    93. Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting. Int Clin Psychopharmacol. 2005 Jan; 20(1):57-8. Kimmel RJ, Irwin SA, Meyer JM. PMID: 15602119.
      View in: PubMed   Mentions:
    94. Decreased bone mineral density in male schizophrenia patients. Schizophr Res. 2005 Jul 01; 76(1):131-3. Lehman D, Meyer JM. PMID: 15927809.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    95. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res. 2004 Dec 01; 71(2-3):195-212. Jin H, Meyer JM, Jeste DV. PMID: 15474892.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    96. Treating the mind and body in schizophrenia: risks and prevention. CNS Spectr. 2004 Oct; 9(10 Suppl 11):25-33. Meyer JM. PMID: 15475874.
      View in: PubMed   Mentions:
    97. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004 Sep 01; 70(1):1-17. Meyer JM, Koro CE. PMID: 15246458.
      View in: PubMed   Mentions:
    98. Quetiapine-induced diabetes with metabolic acidosis. Int Clin Psychopharmacol. 2004 May; 19(3):169-71. Meyer JM, Leckband SG, Loh C, Moutier CY. PMID: 15107661.
      View in: PubMed   Mentions:
    99. Risperidone-induced retrograde ejaculation: case report and review of the literature. Int Clin Psychopharmacol. 2004 Mar; 19(2):111-2. Loh C, Leckband SG, Meyer JM, Turner E. PMID: 15076020.
      View in: PubMed   Mentions:
    100. Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C-seropositive state hospital patients: results from Oregon State Hospital. J Clin Psychiatry. 2003 May; 64(5):540-5. Meyer JM. PMID: 12755656.
      View in: PubMed   Mentions:
    101. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002 May; 63(5):425-33. Meyer JM. PMID: 12019668.
      View in: PubMed   Mentions:
    102. Awareness of obesity and weight issues among chronically mentally ill inpatients: a pilot study. Ann Clin Psychiatry. 2002 Mar; 14(1):39-45. Meyer JM. PMID: 12046639.
      View in: PubMed   Mentions:
    103. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002 Mar; 14(1):59-64. Jin H, Meyer JM, Jeste DV. PMID: 12046641.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    Jonathan's Networks
    Concepts (342)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (16)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-21-g9d46e6c4 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California